Characteristics of gout cases and control study samples (mean ± SD).

*one-way ANOVA, PaPAP>0.05 (in comparison with HC group);bPBP>0.05 (in comparison with HUA group). Statistical significance was set at P≤0.05.tDefined as blood pressure ≥140/90 mmHg or ongoing antihypertensive therapy.cDefined as TG ≥155 mg/dL or intake of lipid lowering medication.f,t,c,pχ2 test:aPBP>0.05 (in comparison with HUA group). GA: gouty arthritis; HUA: hyperuricemia without gout; HC: healthy control subjects; BMI: Body Mass Index, sUA: serum uric acid; GLU: serum glucose; WBC: white blood cell counts; GR: neutrophile granulocytecounts; LY: lymphocyte counts; Mo: monocyte counts; TG: triglycerides; TC: Total Cholesterol; HDL: high density lipoprotein; LDL: low density lipoprotein; VLDL: very low density lipoprotein; apoA1: apolipoprotein A1; apoB100: apolipoprotein B100; ESR: erythrocyte sedimentation rate; CRP: C reactive protein.

*单因素方差分析（one-way ANOVA）：与健康对照受试者（HC，healthy control subjects）比较，PaPAP>0.05；与不伴痛风的高尿酸血症组（HUA，hyperuricemia without gout）比较，bPBP>0.05。本研究设定统计学显著性阈值为P≤0.05。
t：定义为血压≥140/90 mmHg，或正在接受降压药物治疗。
c：定义为甘油三酯（TG，triglycerides）≥155 mg/dL，或正在服用调脂药物。
f、t、c、p项采用χ²检验：与HUA组比较，aPBP>0.05。
缩写释义如下：
GA：痛风性关节炎（gouty arthritis）；HUA：不伴痛风的高尿酸血症（hyperuricemia without gout）；HC：健康对照受试者（healthy control subjects）；BMI：体质量指数（Body Mass Index）；sUA：血清尿酸（serum uric acid）；GLU：血清葡萄糖（serum glucose）；WBC：白细胞计数（white blood cell counts）；GR：中性粒细胞计数（neutrophile granulocyte counts）；LY：淋巴细胞计数（lymphocyte counts）；Mo：单核细胞计数（monocyte counts）；TG：甘油三酯（triglycerides）；TC：总胆固醇（Total Cholesterol）；HDL：高密度脂蛋白（high density lipoprotein）；LDL：低密度脂蛋白（low density lipoprotein）；VLDL：极低密度脂蛋白（very low density lipoprotein）；apoA1：载脂蛋白A1（apolipoprotein A1）；apoB100：载脂蛋白B100（apolipoprotein B100）；ESR：红细胞沉降率（erythrocyte sedimentation rate）；CRP：C反应蛋白（C reactive protein）。